NRX Pharmaceuticals
NRXP
22 hedge funds and large institutions have $4.6M invested in NRX Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
5,067% more call options, than puts
Call options by funds: $310K | Put options by funds: $6K
100% more capital invested
Capital invested by funds: $2.31M → $4.6M (+$2.3M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4.69% more ownership
Funds ownership: 8.67% → 13.36% (+4.7%)
12% less funds holding
Funds holding: 25 → 22 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$419K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$251K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$170K |
| 5 |
Two Sigma Investments
New York
|
+$84.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$231K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$66.3K |
| 3 |
Millennium Management
New York
|
-$60.8K |
| 4 |
Squarepoint
New York
|
-$55.7K |
| 5 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
-$33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCA
26
Sassicaia Capital Advisers
Jericho,
New York
| – | -$33K | -15,000 | Closed |
|
27
Citigroup
New York
| – | -$1.3K | -593 | Closed |
|
28
Group One Trading
Chicago,
Illinois
| – | -$279 | -99 | Closed |
|
|
NA
29
NewEdge Advisors
New Orleans,
Louisiana
| – | -$183 | -83 | Closed |
|
NRXP Hedge Fund Activity: Q1 2025 in Review
22 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2025, worth a combined $4.6M — up 100% from $2.31M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NRXP and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Anson Funds Management, adding an estimated $2.8M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $231K sold.
- 22 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2025, down from 25 in Q4 2024.
- Funds reported $4.6M of NRX Pharmaceuticals stock for Q1 2025, up 100% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q1 2025 and 7 closed out, a net change of -3 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2025 was Anson Funds Management, an estimated $2.8M added.
- The largest NRX Pharmaceuticals seller in Q1 2025 was Susquehanna International Group, an estimated $231K sold.
Based on aggregated 13F filings for Q1 2025.